Compounds and methods for modulation of DUX4
View Patent ↗The present disclosure pertains generally to double-stranded small interfering RNAs that modulate gene expression for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure provides double-stranded small interfering RNAs that modulate DUX4 gene expression. In certain embodiments, the present disclosure provides methods of inhibiting DUX4 gene expression by contacting a cell with double-stranded small interfering RNAs.
1. A double-stranded small interfering RNA, comprising a sense strand and an antisense strand, wherein the antisense strand of the double-stranded small interfering RNA has a nucleobase sequence complementary to at least 12 contiguous nucleobases of:
an equal length portion of nucleobases 5,195-5,220 of SEQ ID NO: 1;
an equal length portion of nucleobases 5,467-5,491 of SEQ ID NO: 1; or
an equal length portion of nucleobases 5,815-5,840 of SEQ ID NO: 1; and
wherein said sense strand is at least 85% complementary to said antisense strand;
wherein said sense strand is at least 85% identical to an equal length portion of SEQ ID NO:1; and
wherein said sense strand comprises at least one modified nucleoside.
2. The double-stranded small interfering RNA of claim 1 , wherein at least one nucleoside of the sense strand of the double-stranded small interfering RNA comprises a modified sugar.
3. The double-stranded small interfering RNA of claim 2 , wherein each nucleoside of the sense strand of the double-stranded small interfering RNA comprises a modified sugar.
4. The double-stranded small interfering RNA of claim 3 , wherein each modified sugar is independently selected from a 2′-F modified sugar or a 2′-OMe modified sugar.
5. The double-stranded small interfering RNA of claim 1 , wherein the sense strand of the double-stranded small interfering RNA comprises at least 1 modified internucleoside linkage.
6. The double-stranded small interfering RNA of claim 5 , wherein the sense strand of the double-stranded small interfering RNA comprises at least 5 modified internucleoside linkages.
7. The double-stranded small interfering RNA of claim 5 , wherein each modified internucleoside linkage is a phosphorothioate internucleoside linkage.
8. A double-stranded small interfering RNA, comprising a sense strand and an antisense strand, wherein the antisense strand of the double-stranded small interfering RNA has a nucleobase sequence comprising at least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 13, 21, 23, 27, 33, 39, or 43; and wherein said sense strand is at least 85% complementary to said antisense strand, wherein said antisense strand is at least 85% complementary to SEQ ID NO: 1, and wherein said sense strand comprises at least one modified nucleoside.
9. The double-stranded small interfering RNA of claim 8 , wherein at least one nucleoside of the sense strand of the double-stranded small interfering RNA comprises a modified sugar.
10. The double-stranded small interfering RNA of claim 9 , wherein each nucleoside of the sense strand of the double-stranded small interfering RNA comprises a modified sugar.
11. The double-stranded small interfering RNA of claim 10 , wherein each modified sugar is independently selected from a 2′-F modified sugar or a 2′-OMe modified sugar.
12. The double-stranded small interfering RNA of claim 8 , wherein the sense strand of the double-stranded small interfering RNA comprises at least 1 modified internucleoside linkage.
13. The double-stranded small interfering RNA of claim 12 , wherein the sense strand of the double-stranded small interfering RNA comprises at least 5 modified internucleoside linkages.
14. The double-stranded small interfering RNA of claim 13 , wherein each modified internucleoside linkage is a phosphorothioate internucleoside linkage.
15. A pharmaceutical composition comprising the double-stranded small interfering RNA of claim 1 and at least one pharmaceutically acceptable diluent or carrier.
16. The double-stranded small interfering RNA of claim 2 , wherein the modified sugar is a 2′-F modified sugar or a 2′-OMe modified sugar.
17. The double-stranded small interfering RNA of claim 9 , wherein the modified sugar is a 2′-F modified sugar or a 2′-OMe modified sugar.